2024 AAAAI HAE Conference Coverage

CE / CME

Key Updates on Hereditary Angioedema: CCO Independent Conference Coverage of the 2024 AAAAI Annual Meeting

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 22, 2024

Expiration: March 21, 2025

Marc Riedl
Marc Riedl, MD, MS

Activity

Progress
1 2
Course Completed

Introduction

At the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI 2024) in Washington, DC, new clinical trial data on hereditary angioedema (HAE) was reported. In this module, Marc Riedl, MD, MS, reviews the clinical implications of several key studies presented at the meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

How many patients with HAE do you provide care for in a typical month?

Based on data presented at AAAAI 2024 by Craig and colleagues, which of the following outcomes would you describe to a patient considering using garadacimab if approved by the FDA for long-term prophylaxis of HAE attacks?

When considering referring a patient to a clinical trial studying sebetralstat for on-demand HAE attacks, which of the following outcomes demonstrated in the phase III KONFIDENT clinical trial should you discuss?

For a patient with frequent HAE attacks, how likely would you be to prescribe a monthly subcutaneous injectable agent for long-term prophylaxis?